Head-to-head evidence
AQUA07 vs Brigatinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: ALK · full Non-Small Cell Lung Cancer pipeline
AQUA07
Developed by Chugai Pharma
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: August 2030 · NCT07617337 (registry estimate)
Brigatinib
Marketed by Takeda Pharmaceutical Company
NCT02737501 · Phase 3 · completed
This was a randomized, open-label active-controlled trial of 275 participants, with progression-free survival assessed by a blinded independent review committee as the primary clinical endpoint. The primary comparison favored brigatinib and was statistically significant, but the lack of participant and investigator blinding limits the strength of the evidence.
Next expected readout: November 2026 · NCT04223596 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AQUA07's landscape · Brigatinib's landscape